Multivariate analysis for aGVHD, relapse, and DFS
Variable* . | RR (95% CI) . | P . |
---|---|---|
Grades 2 to 4 aGVHD† | ||
Patient age | ||
>35 y old | 0.744 (0.479-1.154) | .187 |
<35 y old | ||
Donor-patient gender | ||
Female to male | 1.618 (1.046-2.502) | .031 |
Others | ||
Donor-patient blood type relation | ||
Mismatched | 1.371 (0.918-2.047) | .124 |
Matched | ||
Number of CD34+ cells in stem cell | ||
>5 × 106/kg | 1.088 (0. 722-1.64) | .687 |
<5 × 106/kg | ||
Donor type | ||
URD | 3.525 (1.929-6.439) | <.001 |
HRD | 3.659 (1.997-6.705) | <.001 |
MSD | 1.0 | |
Relapse‡ | ||
Patient age | ||
>35 y old | 0.839 (0.464-1.519) | .698 |
<35 y old | ||
Underlying disease | ||
Lymphoblastic malignancy | 1.644 (0.931-2.904) | .111 |
Myeloid malignancy | ||
Risk classification | ||
High risk | 2.482 (1.333-4.624) | .004 |
Standard risk | ||
Disease status at HSCT | ||
Advanced stage | 1.814 (0.77-4.274) | .262 |
CR | ||
aGVHD | ||
No | 1.349 (0.69-2.638) | .238 |
With aGVHD | ||
cGVHD | ||
No | 2.685 (1.467-4.916) | .001 |
With cGVHD | ||
Donor type | ||
MSD | 1.343 (0.913-1.977) | .044 |
URD | 1.149 (0.791-1.67) | .213 |
HRD | 1.0 | |
High-risk leukemia relapse§ | ||
Patient age | ||
>35 y old | 0.677 (0.348-1.32) | .268 |
<35 y old | ||
Underlying disease | ||
Lymphoblastic disease | 1.285 (0.68-2.429) | .52 |
No lymphoblastic | ||
Disease status at HSCT | ||
Advanced stage | 1.791 (0.751-4.272) | .163 |
CR | ||
aGVHD | ||
No | 1.633 (0.781-3.415) | .259 |
With aGVHD | ||
cGVHD | ||
No | 2.772 (1.365-5.629) | .005 |
With cGVHD | ||
Donor type | ||
MSD or URD | 2.276 (1.056-4.902) | .036 |
HRD | 1.0 | |
DFS|| | ||
Patient age | ||
>35 y old | 1.268 (0.83-1.937) | .272 |
<35 y old | ||
Donor-patient gender | ||
Female to male | 1.207 (0.74-1.97) | .451 |
Others | ||
Donor-patient blood type relationship | ||
Mismatched | 0.939 (0.629-1.403) | .76 |
Matched | ||
Underlying disease | ||
Lymphoblastic disease | 1.701 (1.145-2.527) | .009 |
No lymphoblastic | ||
Cytogenetic risk | ||
High risk | 1.453 (0.917-2.304) | .112 |
Standard risk | ||
Disease status at HSCT | ||
CR | 1.381 (0.709-2.688) | .342 |
Advanced stage | ||
aGVHD | ||
With aGVHD | 1.625 (1.089-2.424) | .017 |
No | ||
cGVHD | ||
No | 2.875 (1.813-4.557) | <.001 |
With cGVHD | ||
Donor type | ||
URD | 1.34 (0.794-2.264) | .273 |
HRD | 1.193 (0.7-2.034) | .516 |
MSD | 1.0 |
Variable* . | RR (95% CI) . | P . |
---|---|---|
Grades 2 to 4 aGVHD† | ||
Patient age | ||
>35 y old | 0.744 (0.479-1.154) | .187 |
<35 y old | ||
Donor-patient gender | ||
Female to male | 1.618 (1.046-2.502) | .031 |
Others | ||
Donor-patient blood type relation | ||
Mismatched | 1.371 (0.918-2.047) | .124 |
Matched | ||
Number of CD34+ cells in stem cell | ||
>5 × 106/kg | 1.088 (0. 722-1.64) | .687 |
<5 × 106/kg | ||
Donor type | ||
URD | 3.525 (1.929-6.439) | <.001 |
HRD | 3.659 (1.997-6.705) | <.001 |
MSD | 1.0 | |
Relapse‡ | ||
Patient age | ||
>35 y old | 0.839 (0.464-1.519) | .698 |
<35 y old | ||
Underlying disease | ||
Lymphoblastic malignancy | 1.644 (0.931-2.904) | .111 |
Myeloid malignancy | ||
Risk classification | ||
High risk | 2.482 (1.333-4.624) | .004 |
Standard risk | ||
Disease status at HSCT | ||
Advanced stage | 1.814 (0.77-4.274) | .262 |
CR | ||
aGVHD | ||
No | 1.349 (0.69-2.638) | .238 |
With aGVHD | ||
cGVHD | ||
No | 2.685 (1.467-4.916) | .001 |
With cGVHD | ||
Donor type | ||
MSD | 1.343 (0.913-1.977) | .044 |
URD | 1.149 (0.791-1.67) | .213 |
HRD | 1.0 | |
High-risk leukemia relapse§ | ||
Patient age | ||
>35 y old | 0.677 (0.348-1.32) | .268 |
<35 y old | ||
Underlying disease | ||
Lymphoblastic disease | 1.285 (0.68-2.429) | .52 |
No lymphoblastic | ||
Disease status at HSCT | ||
Advanced stage | 1.791 (0.751-4.272) | .163 |
CR | ||
aGVHD | ||
No | 1.633 (0.781-3.415) | .259 |
With aGVHD | ||
cGVHD | ||
No | 2.772 (1.365-5.629) | .005 |
With cGVHD | ||
Donor type | ||
MSD or URD | 2.276 (1.056-4.902) | .036 |
HRD | 1.0 | |
DFS|| | ||
Patient age | ||
>35 y old | 1.268 (0.83-1.937) | .272 |
<35 y old | ||
Donor-patient gender | ||
Female to male | 1.207 (0.74-1.97) | .451 |
Others | ||
Donor-patient blood type relationship | ||
Mismatched | 0.939 (0.629-1.403) | .76 |
Matched | ||
Underlying disease | ||
Lymphoblastic disease | 1.701 (1.145-2.527) | .009 |
No lymphoblastic | ||
Cytogenetic risk | ||
High risk | 1.453 (0.917-2.304) | .112 |
Standard risk | ||
Disease status at HSCT | ||
CR | 1.381 (0.709-2.688) | .342 |
Advanced stage | ||
aGVHD | ||
With aGVHD | 1.625 (1.089-2.424) | .017 |
No | ||
cGVHD | ||
No | 2.875 (1.813-4.557) | <.001 |
With cGVHD | ||
Donor type | ||
URD | 1.34 (0.794-2.264) | .273 |
HRD | 1.193 (0.7-2.034) | .516 |
MSD | 1.0 |
RR, relative risk.
The donor types and clinical factors included in the multivariate analysis were stated in the table.
Multivariate analysis was performed in 3 transplantation cohorts including 304 patients.
Multivariate analysis was performed in 3 transplantation cohorts including 304 patients.
Multivariate analysis was performed in 193 high-risk patients.
Multivariate analysis was performed in 3 transplantation cohorts including 305 patients.